In the Phase 2 TIPO-1 trial, the most common adverse events were dry mouth, nausea, constipation, hard stools, and insomnia. A dose-related increase in heart rate was also seen, most notable at the higher doses, while blood pressure changes were smaller at the lower doses.[1]
Reviewed for accuracy · Last reviewed July 8, 2026Because tesofensine works by raising noradrenaline and dopamine signaling, its stimulant-like effects on heart rate and sleep are part of the expected profile rather than a surprise. As an investigational drug with one main human trial, its longer-term safety in people is not well characterized, and there is no approved label documenting rarer risks.
The cardiovascular and sleep effects are why higher doses drew caution. Anyone considering it should be aware there is no approved monitoring protocol, and cardiovascular history is a common reason clinicians would advise against stimulant-type appetite suppressants.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.